229 related articles for article (PubMed ID: 19387352)
1. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study.
Hansson J; Lind L; Hulthe J; Sundström J
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):297-303. PubMed ID: 19387352
[TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.
Tayebjee MH; Nadar SK; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):770-4. PubMed ID: 15363818
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
4. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study.
Sundström J; Evans JC; Benjamin EJ; Levy D; Larson MG; Sawyer DB; Siwik DA; Colucci WS; Sutherland P; Wilson PW; Vasan RS
Circulation; 2004 Jun; 109(23):2850-6. PubMed ID: 15173025
[TBL] [Abstract][Full Text] [Related]
5. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.
Sundström J; Evans JC; Benjamin EJ; Levy D; Larson MG; Sawyer DB; Siwik DA; Colucci WS; Wilson PW; Vasan RS
Eur Heart J; 2004 Sep; 25(17):1509-16. PubMed ID: 15342170
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
7. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Arnold M; Demers C; McKelvie RS; Liu PP
J Card Fail; 2006 Sep; 12(7):514-9. PubMed ID: 16952784
[TBL] [Abstract][Full Text] [Related]
8. Plasma metalloproteinase levels and left ventricular remodeling in hypertrophic cardiomyopathy in patients with an identical mutation.
Kitaoka H; Kubo T; Okawa M; Takenaka N; Baba Y; Yamasaki N; Matsumura Y; Furuno T; Doi YL
J Cardiol; 2011 Nov; 58(3):261-5. PubMed ID: 21890325
[TBL] [Abstract][Full Text] [Related]
9. [Matrix metalloproteinases: significance in remodeling of the myocardium in valvular heart disease].
Goncharova NS; Moiseeva OM; Shliakhto EV; Aleshina GM
Kardiologiia; 2007; 47(12):49-52. PubMed ID: 18260979
[TBL] [Abstract][Full Text] [Related]
10. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.
Iwanaga Y; Aoyama T; Kihara Y; Onozawa Y; Yoneda T; Sasayama S
J Am Coll Cardiol; 2002 Apr; 39(8):1384-91. PubMed ID: 11955860
[TBL] [Abstract][Full Text] [Related]
11. Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure.
Spoto B; Testa A; Parlongo RM; Tripepi G; D'Arrigo G; Mallamaci F; Zoccali C
Nephrol Dial Transplant; 2012 Jun; 27(6):2440-5. PubMed ID: 22199358
[TBL] [Abstract][Full Text] [Related]
12. [Ventricular remodeling and matrix metalloproteinase-1 and its tissue inhibitor of metalloproteinase-1 in serum in third trimester of pregnant women with cardiac disease.].
Zhang ZL; Lin JH; Tao RQ
Zhonghua Fu Chan Ke Za Zhi; 2009 Oct; 44(10):731-5. PubMed ID: 20078957
[TBL] [Abstract][Full Text] [Related]
13. Impact of metalloproteinases on left ventricular remodeling and heart failure events in patients with hypertrophic cardiomyopathy.
Kitaoka H; Kubo T; Okawa M; Hayato K; Yamasaki N; Matsumura Y; Doi YL
Circ J; 2010 Jun; 74(6):1191-6. PubMed ID: 20453389
[TBL] [Abstract][Full Text] [Related]
14. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.
Niemirska A; Litwin M; Trojanek J; Gackowska L; Kubiszewska I; Wierzbicka A; Kułaga Z; Michałkiewicz J
J Hypertens; 2016 Sep; 34(9):1815-22. PubMed ID: 27379542
[TBL] [Abstract][Full Text] [Related]
15. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
Poulsen SH
Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
[TBL] [Abstract][Full Text] [Related]
17. [Metalloproteinase activity of the blood in patients with arterial hypertension with paroxysmal form of atrial fibrillation].
Khezheva FM; Mazur NA; Masenko VP
Kardiologiia; 2007; 47(12):10-4. PubMed ID: 18260972
[TBL] [Abstract][Full Text] [Related]
18. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
19. Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart.
Vianello A; Caponi L; Franzoni F; Galetta F; Rossi M; Taddei M; Malvaldi G; Pietrini P; Santoro G
Clin Sci (Lond); 2009 Jul; 117(4):157-64. PubMed ID: 19196241
[TBL] [Abstract][Full Text] [Related]
20. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study.
Vasan RS; Evans JC; Benjamin EJ; Levy D; Larson MG; Sundstrom J; Murabito JM; Sam F; Colucci WS; Wilson PW
Hypertension; 2004 May; 43(5):957-62. PubMed ID: 15007028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
